Prostate cryotherapy: Current status

Chad Ritch, Aaron E. Katz

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Purpose of review Minimally invasive options to treat low-risk prostate cancer are more desirable than radical therapy. Technological improvements in cryotherapy have increased its use, and long-term data on its efficacy are emerging. In this review, we discuss contemporary data on cryotherapy with specific focus on studies using the newest technology. Recent findings With respect to biochemical recurrence rates, cryotherapy appears to be as effective for low-risk prostate cancer as other treatment modalities. The definition of recurrence remains problematic, though contemporary studies are more consistently using both the American Society for Therapeutic Radiation Oncology and Phoenix criteria. Erectile dysfunction rates are universally high after whole-gland cryoablation, but incontinence and urethrorectal fistula rates appear to be low with third-generation cryo systems. Focal cryotherapy has encouraging short-term efficacy in terms of biochemical disease-free survival rate for unifocal disease, and rates of erectile dysfunction are dramatically lower than those seen with whole-gland cryoablation. Summary Cryosurgery has a promising role in primary and salvage treatment of select prostate cancer patients. Focal cryotherapy for unilateral disease offers the added benefit of minimal adverse effects. Long-term data are emerging to support cryosurgery, and large multicenter databases have been developed to answer questions regarding optimal treatment outcomes and patterns.

Original languageEnglish (US)
Pages (from-to)177-181
Number of pages5
JournalCurrent Opinion in Urology
Volume19
Issue number2
DOIs
StatePublished - Mar 2009
Externally publishedYes

Fingerprint

Cryotherapy
Cryosurgery
Prostate
Prostatic Neoplasms
Erectile Dysfunction
Recurrence
Salvage Therapy
Radiation Oncology
Disease-Free Survival
Fistula
Therapeutics
Survival Rate
Databases
Technology

Keywords

  • Cryosurgery
  • Focal therapy
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Prostate cryotherapy : Current status. / Ritch, Chad; Katz, Aaron E.

In: Current Opinion in Urology, Vol. 19, No. 2, 03.2009, p. 177-181.

Research output: Contribution to journalArticle

Ritch, Chad ; Katz, Aaron E. / Prostate cryotherapy : Current status. In: Current Opinion in Urology. 2009 ; Vol. 19, No. 2. pp. 177-181.
@article{869b9ea4abf84b9d9bf53f0e3b30f12a,
title = "Prostate cryotherapy: Current status",
abstract = "Purpose of review Minimally invasive options to treat low-risk prostate cancer are more desirable than radical therapy. Technological improvements in cryotherapy have increased its use, and long-term data on its efficacy are emerging. In this review, we discuss contemporary data on cryotherapy with specific focus on studies using the newest technology. Recent findings With respect to biochemical recurrence rates, cryotherapy appears to be as effective for low-risk prostate cancer as other treatment modalities. The definition of recurrence remains problematic, though contemporary studies are more consistently using both the American Society for Therapeutic Radiation Oncology and Phoenix criteria. Erectile dysfunction rates are universally high after whole-gland cryoablation, but incontinence and urethrorectal fistula rates appear to be low with third-generation cryo systems. Focal cryotherapy has encouraging short-term efficacy in terms of biochemical disease-free survival rate for unifocal disease, and rates of erectile dysfunction are dramatically lower than those seen with whole-gland cryoablation. Summary Cryosurgery has a promising role in primary and salvage treatment of select prostate cancer patients. Focal cryotherapy for unilateral disease offers the added benefit of minimal adverse effects. Long-term data are emerging to support cryosurgery, and large multicenter databases have been developed to answer questions regarding optimal treatment outcomes and patterns.",
keywords = "Cryosurgery, Focal therapy, Prostate cancer",
author = "Chad Ritch and Katz, {Aaron E.}",
year = "2009",
month = "3",
doi = "10.1097/MOU.0b013e32831e16ce",
language = "English (US)",
volume = "19",
pages = "177--181",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Prostate cryotherapy

T2 - Current status

AU - Ritch, Chad

AU - Katz, Aaron E.

PY - 2009/3

Y1 - 2009/3

N2 - Purpose of review Minimally invasive options to treat low-risk prostate cancer are more desirable than radical therapy. Technological improvements in cryotherapy have increased its use, and long-term data on its efficacy are emerging. In this review, we discuss contemporary data on cryotherapy with specific focus on studies using the newest technology. Recent findings With respect to biochemical recurrence rates, cryotherapy appears to be as effective for low-risk prostate cancer as other treatment modalities. The definition of recurrence remains problematic, though contemporary studies are more consistently using both the American Society for Therapeutic Radiation Oncology and Phoenix criteria. Erectile dysfunction rates are universally high after whole-gland cryoablation, but incontinence and urethrorectal fistula rates appear to be low with third-generation cryo systems. Focal cryotherapy has encouraging short-term efficacy in terms of biochemical disease-free survival rate for unifocal disease, and rates of erectile dysfunction are dramatically lower than those seen with whole-gland cryoablation. Summary Cryosurgery has a promising role in primary and salvage treatment of select prostate cancer patients. Focal cryotherapy for unilateral disease offers the added benefit of minimal adverse effects. Long-term data are emerging to support cryosurgery, and large multicenter databases have been developed to answer questions regarding optimal treatment outcomes and patterns.

AB - Purpose of review Minimally invasive options to treat low-risk prostate cancer are more desirable than radical therapy. Technological improvements in cryotherapy have increased its use, and long-term data on its efficacy are emerging. In this review, we discuss contemporary data on cryotherapy with specific focus on studies using the newest technology. Recent findings With respect to biochemical recurrence rates, cryotherapy appears to be as effective for low-risk prostate cancer as other treatment modalities. The definition of recurrence remains problematic, though contemporary studies are more consistently using both the American Society for Therapeutic Radiation Oncology and Phoenix criteria. Erectile dysfunction rates are universally high after whole-gland cryoablation, but incontinence and urethrorectal fistula rates appear to be low with third-generation cryo systems. Focal cryotherapy has encouraging short-term efficacy in terms of biochemical disease-free survival rate for unifocal disease, and rates of erectile dysfunction are dramatically lower than those seen with whole-gland cryoablation. Summary Cryosurgery has a promising role in primary and salvage treatment of select prostate cancer patients. Focal cryotherapy for unilateral disease offers the added benefit of minimal adverse effects. Long-term data are emerging to support cryosurgery, and large multicenter databases have been developed to answer questions regarding optimal treatment outcomes and patterns.

KW - Cryosurgery

KW - Focal therapy

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=61349130701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61349130701&partnerID=8YFLogxK

U2 - 10.1097/MOU.0b013e32831e16ce

DO - 10.1097/MOU.0b013e32831e16ce

M3 - Article

C2 - 19195130

AN - SCOPUS:61349130701

VL - 19

SP - 177

EP - 181

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 2

ER -